KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Jazz Pharmaceuticals (JAZZ) Gross Margin (2016 - 2025)

Historic Gross Margin for Jazz Pharmaceuticals (JAZZ) over the last 17 years, with Q3 2025 value amounting to 88.56%.

  • Jazz Pharmaceuticals' Gross Margin fell 8700.0% to 88.56% in Q3 2025 from the same period last year, while for Sep 2025 it was 117.47%, marking a year-over-year increase of 280900.0%. This contributed to the annual value of 89.05% for FY2024, which is 4100.0% up from last year.
  • According to the latest figures from Q3 2025, Jazz Pharmaceuticals' Gross Margin is 88.56%, which was down 8700.0% from 88.88% recorded in Q2 2025.
  • In the past 5 years, Jazz Pharmaceuticals' Gross Margin ranged from a high of 93.39% in Q1 2021 and a low of 82.67% during Q3 2021
  • For the 5-year period, Jazz Pharmaceuticals' Gross Margin averaged around 87.45%, with its median value being 88.36% (2025).
  • Its Gross Margin has fluctuated over the past 5 years, first plummeted by -101200bps in 2021, then skyrocketed by 66200bps in 2023.
  • Quarter analysis of 5 years shows Jazz Pharmaceuticals' Gross Margin stood at 84.82% in 2021, then dropped by -2bps to 82.78% in 2022, then rose by 8bps to 89.4% in 2023, then dropped by -1bps to 88.17% in 2024, then rose by 0bps to 88.56% in 2025.
  • Its last three reported values are 88.56% in Q3 2025, 88.88% for Q2 2025, and 88.17% during Q4 2024.